Literature DB >> 26552414

First Oncolytic Viral Therapy for Melanoma.

Alissa Poh.   

Abstract

The FDA has approved talimogene laherparepvec, or T-VEC, to treat surgically unresectable skin and lymph node lesions in patients with advanced melanoma. T-VEC is the first oncolytic viral therapy to gain regulatory endorsement, based on data from the OPTiM study. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26552414     DOI： 10.1158/2159-8290.CD-NB2015-158

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  16 in total

1.  First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors.

Authors:  David Ruano; José A López-Martín; Lucas Moreno; Álvaro Lassaletta; Francisco Bautista; Maitane Andión; Carmen Hernández; África González-Murillo; Gustavo Melen; Ramón Alemany; Luis Madero; Javier García-Castro; Manuel Ramírez
Journal:  Mol Ther       Date:  2020-01-21       Impact factor: 11.454

Review 2.  Oncolytic viruses: overcoming translational challenges.

Authors:  Jordi Martinez-Quintanilla; Ivan Seah; Melissa Chua; Khalid Shah
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

3.  High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment.

Authors:  Jinhu Ma; Chunxue Zhang; Gang Shi; Dan Yue; Yongheng Shu; Shichuan Hu; Zhongbing Qi; Yanwei Chen; Bin Zhang; Yong Zhang; Anliang Huang; Chao Su; Yan Zhang; Hongxin Deng; Ping Cheng
Journal:  Mol Ther       Date:  2021-09-20       Impact factor: 11.454

Review 4.  Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.

Authors:  Guy Ungerechts; Sascha Bossow; Barbara Leuchs; Per S Holm; Jean Rommelaere; Matt Coffey; Rob Coffin; John Bell; Dirk M Nettelbeck
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-06       Impact factor: 6.698

Review 5.  Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.

Authors:  Hanne Locy; Sven de Mey; Wout de Mey; Mark De Ridder; Kris Thielemans; Sarah K Maenhout
Journal:  Front Immunol       Date:  2018-12-11       Impact factor: 7.561

6.  Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC.

Authors:  Jiayu Zhang; Ying Liu; Jingyi Tan; Yanming Zhang; Chun-Wa Wong; Ziqing Lin; Xincheng Liu; Max Sander; Xiaozhi Yang; Lebin Liang; Deli Song; Jia Dan; Yuwei Zhou; Jing Cai; Yuan Lin; Jiankai Liang; Jun Hu; Guangmei Yan; Wenbo Zhu
Journal:  Oncogene       Date:  2021-06-21       Impact factor: 9.867

Review 7.  Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy.

Authors:  Prapti H Mody; Sushila Pathak; Laura K Hanson; Juliet V Spencer
Journal:  Virology (Auckl)       Date:  2020-05-29

Review 8.  Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.

Authors:  Huitao Liu; Honglin Luo
Journal:  Viruses       Date:  2021-06-05       Impact factor: 5.048

9.  Novel transcription regulatory sequences and factors of the immune evasion protein ICP47 (US12) of herpes simplex viruses.

Authors:  Jun-Ting Cheng; Ying-Ying Wang; Lin-Zhong Zhu; Ying Zhang; Wen-Qi Cai; Zi-Wen Han; Yang Zhou; Xian-Wang Wang; Xiao-Chun Peng; Ying Xiang; Hui-Yu Yang; Shu-Zhong Cui; Zhaowu Ma; Bing-Rong Liu; Hong-Wu Xin
Journal:  Virol J       Date:  2020-07-10       Impact factor: 4.099

10.  Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.

Authors:  Shiyun Dai; Yun Lv; Weidong Xu; Yuefeng Yang; Chao Liu; Xiwen Dong; Huan Zhang; Bellur S Prabhakar; Ajay V Maker; Prem Seth; Hua Wang
Journal:  Cancer Gene Ther       Date:  2020-04-20       Impact factor: 5.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.